Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).

This project seeks to adapt and test the existing Tough Talks app to address COVID vaccine hesitancy among African American young adults (AA-YA) aged 18-29.

In this study, we want to learn more about a program (STOMP) designed to improve chronic pain in people living with HIV.

The purpose of this study is to conduct interviews to hear people's thoughts and feedback on various aspects of conducting syphilis vaccine research at UNC-Chapel Hill and to ask them to complete a brief online survey after their interviews. The information that participants provide will help the clinical trial researchers to better understand what concerns people might have about syphilis vaccine research and to design clinical trials that are acceptable to potential vaccine research participants.

The purpose of this research study is to learn from YMSM about their perceptions of two phone apps designed to increase HIV testing, PrEP uptake, and other prevention strategies. We also want to learn about whether the apps encourage behavior change, as they are designed to do.

To evaluate safety and efficacy of therapeutic vaccination with chimpanzee adenovirus (ChAdV)- and poxvirus modified vaccinia Ankara (MVA)-vectored vaccines in a sequential regimen with the Toll-like Receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1.

To better understand whether people in jail have ever received COVID-19 testing and vaccination and whether they would be will to receive these services in jail and after their release.

The purpose of this study is to see how safe and tolerable SLGN is, and how well it reduces the amount of hepatitis B virus in people with CHB and HIV. Results from this study could help evaluate whether SLGN can lower the amount of hepatitis B virus in blood and prevent illness in people with CHB and HIV, without the need for life-long therapy. SLGN has not been tested in people with HIV

To increase access to Pre-Exposure Prophylaxis (PrEP) across North Carolina. HIV Pre-Exposure Prophylaxis (PrEP) medication has been proven to be effective at preventing HIV infection when taken as prescribed. Even though PrEP has been shown to be effective, not all health care settings currently offer PrEP to their patients. Part of the reason for this is that there are not enough health care providers who prescribe PrEP, and, some people have difficulty getting the cost of PrEP and PrEP care covered. The purpose of this study is to test new ways to increase access to PrEP for people in North Carolina. The intervention will test whether providing access to resources related to PrEP care at health department sexually transmitted infection (STI) clinics will increase the number of people who start using PrEP.

The primary objective of this study is to document epidemiological and ecological trends in both outpatient and inpatient cases of ARI in Kasese District in southwestern Uganda. We will also establish of a network of healthcare facilities to conduct research on preventing and improving the management of ARI in this region.